Are you interested in learning more about Niemann-Pick type C disease?
Prof. Peter Bauer, CSO of CENTOGENE, introduces you to NP-C and discusses the importance of a robust biomarker for the diagnosis and monitoring of this disease.
Discover how our screening programs for NP-C can enable diagnosis, prediction and therapy monitoring for your patients.
- CENTOGENE’s integrated diagnostic concept for rare diseases
- The challenge with rare variant classification and medical interpretation
- The value of biomarkers in rare diseases – biomarkers in Niemann-Pick type C disease
Prof. Peter Bauer, M.D., serves as CENTOGENE’s Chief Genomic Officer, where he combines […]